| Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects | Frank Vinluan | 10/15/20 | Boston |
| Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma | Frank Vinluan | 10/13/20 | San Diego |
| FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats | Frank Vinluan | 10/09/20 | Europe |
| In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug | Frank Vinluan | 10/08/20 | National |
| Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries | Frank Vinluan | 10/01/20 | Europe |
| Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2 | Frank Vinluan | 09/23/20 | Europe |
| Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug | Frank Vinluan | 09/16/20 | Wisconsin |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Satsuma Pharma’s Migraine Drug Fails to Beat Placebo in Phase 3 Test | Frank Vinluan | 09/10/20 | San Francisco |
| AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase | Frank Vinluan | 09/04/20 | National |
| Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout | Sarah de Crescenzo | 08/26/20 | San Diego |
| MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T | Frank Vinluan | 08/03/20 | Europe |
| Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test | Frank Vinluan | 07/28/20 | New York |
| Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test | Frank Vinluan | 07/15/20 | Boston |
| Ultragenyx Pharma Wins FDA’s First Drug Nod for Rare Metabolic Disorder | Frank Vinluan | 06/30/20 | San Francisco |
| Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug | Frank Vinluan | 06/05/20 | New York |
| Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact | Frank Vinluan | 05/27/20 | San Francisco |
| Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola | Frank Vinluan | 05/05/20 | Boston |
| FDA Approves Incyte Drug, First Ever for Rare Bile Duct Cancer | Frank Vinluan | 04/20/20 | National |
| GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year | Frank Vinluan | 04/14/20 | National |
| A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy | Frank Vinluan | 03/31/20 | Raleigh Durham |
| Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data | Frank Vinluan | 03/10/20 | Boston |
| NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data | Sarah de Crescenzo | 02/24/20 | San Francisco |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come | Frank Vinluan | 02/10/20 | New York |
| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| CEOs of Women’s Health Companies Fight to Open Investment Floodgates | Sarah de Crescenzo | 01/22/20 | San Diego |
| Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug | Frank Vinluan | 01/13/20 | National |
| Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans | Frank Vinluan | 01/13/20 | Boston |
| Apellis Rare Blood Disease Drug Tops Alexion’s in Head-to-Head Test | Frank Vinluan | 01/07/20 | Boston |
